Placebo + Evolocumab
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Atherosclerotic Vascular Disease
Conditions
Atherosclerotic Vascular Disease, Type2 Diabetes, Microvascular Dysfunction
Trial Timeline
Jun 3, 2019 → Nov 15, 2021
NCT ID
NCT03829046About Placebo + Evolocumab
Placebo + Evolocumab is a approved stage product being developed by Amgen for Atherosclerotic Vascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03829046. Target conditions include Atherosclerotic Vascular Disease, Type2 Diabetes, Microvascular Dysfunction.
What happened to similar drugs?
6 of 20 similar drugs in Atherosclerotic Vascular Disease were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03829046 | Approved | Completed |
Competing Products
20 competing products in Atherosclerotic Vascular Disease